ANDI (Advanced Neuro Diagnostic Imaging)
AI-powered white matter imaging software for clinical neurological diagnostics
Software · Cloud SaaSCompany source
Company profile
About Imeka Solutions
Imeka Solutions is a medical imaging technology company specializing in advanced white matter brain imaging for clinical use. The company has developed ANDI (Advanced Neuro Diagnostic Imaging), an FDA 510(k) cleared clinical software platform that combines Diffusion Tensor Imaging (DTI) with artificial intelligence to analyze white matter microstructure in unprecedented detail. ANDI is a fully automated, validated quantitative clinical software that transforms raw MRI data into comprehensive reports ready for clinical use, with data collection possible in as little as five minutes on standard MRI machines. The technology focuses on measuring neuroinflammation, axonal integrity, myelin integrity, and overall white matter health, with particular expertise in traumatic brain injury (TBI), Alzheimer's disease (AD), multiple sclerosis (MS), and other white matter pathologies. Imeka's technology is backed by years of research and development with pharmaceutical companies and MRI manufacturers, and the company continues to validate novel biomarkers to advance their clinical tools. The company serves clinicians and healthcare providers seeking detailed, non-invasive brain imaging analysis to improve patient outcomes. Imeka maintains offices in both Canada and the United States, with a team led by experienced executives and advised by prominent figures in neuroradiology and medical imaging.
Company description Imeka Solutions official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Imeka Solutions?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Alzheimer's Disease (AD)
- Multiple Sclerosis (MS)
- Neurodegenerative diseases
- Neuroinflammation
- Traumatic Brain Injury (TBI)
- White matter pathologies
Who it serves
- Clinicians
- Health systems
- Healthcare providers
- Radiology practices
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsCanada · United States
Company sourceOfficial website
Company milestones
Platform expansion
ANDI 2.0 launched with brain volumetry capabilities (2025). Exhibited at RSNA 2025 in Chicago. Scheduled to present at ASNR in Philadelphia (May 2025). Featured in multiple peer-reviewed publications in 2024-2025.
Partnerships
Recorded partners
- MRI manufacturers (unnamed)
- Pharmaceutical companies (unnamed)
- RadNet Inc.
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Longitudinal visualization tools for advanced characterization of multiple sclerosis lesions using diffusion MRI and magnetization transfer imaging metrics.Brain structure & function · Mar 26, 2026
Association of Cortical Free Water With Brain Tau Tangle Load in the Alzheimer Disease Continuum.Neurology · Mar 10, 2026
Challenges and best practices when using ComBAT to harmonize diffusion MRI data.Scientific reports · Nov 24, 2025
Considerations and recommendations from the ISMRM diffusion study group for preclinical diffusion MRI: Part 1: In vivo small-animal imaging.Magnetic resonance in medicine · Jun 1, 2025
Considerations and recommendations from the ISMRM Diffusion Study Group for preclinical diffusion MRI: Part 3-Ex vivo imaging: Data processing, comparisons with microscopy, and tractography.Magnetic resonance in medicine · Jun 1, 2025
Considerations and recommendations from the ISMRM diffusion study group for preclinical diffusion MRI: Part 2-Ex vivo imaging: Added value and acquisition.Magnetic resonance in medicine · Jun 1, 2025
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
ANDI 2.0K252298 · 510k · Oct 22, 2025
ANDIK230913 · 510k · Jul 25, 2023
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Data collection time
As little as 5 minutes on standard MRI machine
White matter analysis
Measures neuroinflammation, axonal integrity, myelin integrity, and white matter health in detail
Washington School of Medicine (Dr. Cyrus Raji team)
Clinical validation and research application of ANDI for neuroimaging analysis
Independent scientific article published in BMC Neurology validating ANDI technology
CENTER-TBI Study Group
Predicting recovery in patients with mild traumatic brain injury using diffusion tensor imaging
Publication in eClinicalMedicine (The Lancet Discovery Science) featuring Imeka's technology
RadNet Inc.
Advanced imaging technology implementation and clinical adoption
Strategic advisory relationship with Chief Technology Officer Dr. Lawrence Tanenbaum
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Jean-René Bélanger
Chief Executive Officer
Valérie Lacroix
Chief Operating Officer, Executive Vice President
Jean-Christophe Houde
Technical Product Owner
Maxime Descoteaux
Co-Founder, Chief Science Officer
Pierre-Marc Jodoin
Co-Founder
06 · Company updates
Updates from Imeka Solutions
Recent articles published on Imeka Solutions's official website.
We’ll be at this year’s ASNR!
Read on Imeka SolutionsImeka’s technology featured in new publication
Read on Imeka SolutionsImekaTM and GE Healthcare collaborate to advance precision medicine for brain health
Read on Imeka SolutionsANDITM featured in new publication
Read on Imeka SolutionsImekaTM receives FDA 510(k) clearance for ANDI medical device
Read on Imeka Solutions07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.